Audentes Therapeutics: Japan's Astellas (OTC:ALPMY) to acquire Audentes Therapeutics for $60/share in cash
- In 2018, Novartis (NVS) paid $8.7 bln for AveXis (AVXS).
- In February, Roche (RHHBY) agreed to pay $4.8 bln to acquire Spark Therapeutics (ONCE). This deal has yet to close due to ongoing regulatory concerns.
- In March, Biogen (BIIB) paid $800 mln to acquire Nightstar Therapeutics (NITE).